CORC

在结果中检索

CORC

浏览/检索结果: 共90条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study 期刊论文
BLOOD ADVANCES, 2023, 卷号: 7
作者:  Bachy, Emmanuel;  Savage, Kerry J.;  Huang, Huiqiang;  Kwong, Yok-Lam;  Gritti, Giuseppe
收藏  |  浏览/下载：12/0  |  提交时间：2023/11/10
The Prognostic Utility of F-18-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Analyses of Metabolic Response Rates in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients 期刊论文
FRONTIERS IN ONCOLOGY, 2022, 卷号: 12
作者:  Li, Cong;  Yu, Haifeng;  Chen, Xi;  Han, Shuiyun;  Peng, Shuailing
收藏  |  浏览/下载：15/0  |  提交时间：2022/12/23
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma 期刊论文
BLOOD ADVANCES, 2022, 卷号: 6
作者:  Yang, Haiyan;  Xiang, Bing;  Song, Yuqin;  Zhang, Huilai;  Zhao, Weili
收藏  |  浏览/下载：16/0  |  提交时间：2022/12/23
Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis 期刊论文
CLINICAL CANCER RESEARCH, 2022, 卷号: 28
作者:  Song, Yuqin;  Gao, Quanli;  Zhang, Huilai;  Fan, Lei;  Zhou, Jianfeng
收藏  |  浏览/下载：29/0  |  提交时间：2022/05/05
High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma 期刊论文
BMC CANCER, 2022, 卷号: 22
作者:  Chen, Xi;  Kong, Haiying;  Luo, Linxiang;  Han, Shuiyun;  Lei, Tao
收藏  |  浏览/下载：42/0  |  提交时间：2022/02/14
Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial 期刊论文
BLOOD, 2021, 卷号: 138
作者:  Ding, Kaiyang;  Liu, Hailing;  Yang, Haiyan;  Cao, Lei;  Zhao, Xiaoli
收藏  |  浏览/下载：8/0  |  提交时间：2022/12/23
The Interim Efficacy of Epigenetic Priming Regimen with Azacytidine and Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma 期刊论文
BLOOD, 2021, 卷号: 138
作者:  Ding, Kaiyang;  Shi, Xiao;  Yang, Haiyan;  Cao, Lei;  Zhao, Xiaoli
收藏  |  浏览/下载：8/0  |  提交时间：2022/12/23
Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study. 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39
作者:  Song, Yuqin;  Gao, Quanli;  Zhang, Huilai;  Fan, Lei;  Zhou, Jianfeng
收藏  |  浏览/下载：28/0  |  提交时间：2022/01/10
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial 期刊论文
LANCET HAEMATOLOGY, 2019, 卷号: 6, 期号: 1
作者:  Zhang, Wei;  Gao, Yuhuan;  Jin, Zhengming;  Zhou, Jianfeng;  Jin, Chuan
收藏  |  浏览/下载：44/0  |  提交时间：2019/12/05
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2019, 卷号: 37, 期号: 14
作者:  Leonard, John P.;  Trneny, Marek;  Izutsu, Koji;  Fowler, Nathan H.;  Hong, Xiaonan
收藏  |  浏览/下载：25/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace